C0040624||Transactivation
C1514562||Domain
C1454487||Human c-Myc
C0384782||Poly(Q)
C0235032||Neurotoxicity
C0013138||Drosophila
C0684309||Disease Models
C0384782||Polyglutamine
C0384782||poly(Q)
C0012634||disorders
C0020179||Huntington's disease
C0020179||Huntington's disease
C0087012||spinocerebellar ataxias
C0027765||neurological disorders
C0205229||expanded
C0384782||poly(Q)
C0079941||coding region
C0017337||gene
C0699748||Pathogenesis
C0012634||disorders
C0007634||cells
C1564139||mutant proteins
C0007637||inclusion bodies
C0007637||inclusion bodies
C0007634||cellular
C0040648||transcription factors
C0033684||proteins
C0027882||neuronal
C0162638||apoptosis
C0041904||upregulation
C1317967||Drosophila myc
C1317967||Drosophila myc
C0384782||poly(Q)
C0600688||toxicity
C0013138||Drosophila
C1454487||human c-myc proto-oncogene
C1454487||c-Myc
C0597298||isoform
C0384782||poly(Q)
C0235032||neurotoxicity
C1254351||drug
C1317967||Drosophila myc
C1171362||induced expression
C1454487||human c-myc
C0384782||poly(Q)
C0235032||neurotoxicity
C0597298||isoforms
C1454487||c-Myc
C1454487||c-Myc2 protein
C1454487||c-Myc1
C1454487||c-MycS
C0040624||transactivation
C1514562||domain
C0040624||transactivation
C1514562||domain
C1454487||c-Myc
C1254351||drug molecules
C0384782||poly(Q)
C0012634||disorders